Ophthalmic agents in the prevention and treatment of computer vision syndrome

DOI: https://doi.org/10.29296/25877305-2021-07-06
Download full text PDF
Issue: 
7
Year: 
2021

T. Potupchik(1), Candidate of Medical Sciences, E. Okladnikova(1), Candidate of Medical
Sciences, L. Evert(2), MD; E. Belova(1); Yu. Kostyuchenko(2) (1)Prof. V.F. Voino-Yasenetsky Krasnoyarsk
State Medical University, Ministry of Health of Russia (2)Research Institute for Medical Problems of the
North, Federal Research Center «Krasnoyarsk Research Center», Siberian Branch, Russian Academy of Sciences

The paper reviews information on the use of ophthalmic agents to prevent and treat computer vision syndrome (CVS) and dry eye syndrome (DES). Studies show that the leading place in the therapy of CVS and DES is occupied by synthetic keratoprotectors, tear substitutes, and artificial tear products, which can be recommended for use in ophthalmology practice as first-line agents for the prevention and treatment of these diseases. It has been proven that ophthalmic solutions containing sodium hyaluronate and lipid-based agents effectively improve the damaged ocular surface and tear stability and can be auxiliary or alternative agents for the prevention and treatment of this pathology.
Keywords: 
ophthalmology
computer vision syndrome
dry eye syndrome
keratoprotectors
ophthalmic agents

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Baryshnikova D.A. Vzgljad oftal'mologa: vybor uvlazhnjajuschih kapel' dlja glaz [Baryshnikova D. A. The view of an ophthalmologist: the choice of moisturizing drops for the eyes. (in Russ.)]. Rezhim dostupa / Access mode: http://www.medlinks.ru/article.php?sid=69043
  2. Brzheskij V.V. Algoritm vybora slezozamestitel'noj terapii u patsientov v ambulatornoj praktike. RMZh. Klinicheskaja oftal'mologija. 2018; 18 (1): 13–9 [Brzhesky V.V. Algorithm of selecting the tear replacement therapy in ambulatory practice. RMJ. Clinical ophthalmology. 2018; 18 (1): 13–9 (in Russ.)].
  3. Brzheskij V.V. Komp'juternyj zritel'nyj sindrom i sindrom «suhogo glaza» [Brzhesky V.V. Computer visual syndrome and «dry eye» syndrome. (in Russ.)]. Rezhim dostupa / Access mode: https://eyepress.ru/article.aspx?42434
  4. Gazizova I.R., Tihomirova I.Ju. Klinicheskie effekty Vizomitina na poverhnost' glaza. Novosti glaukomy. 2015; 33 (1): 100–1 [Gazizova I.R., Tikhomirova I.Yu. Clinical effects of Visomitin on the surface of the eye. Glaucoma news. 2015; 33 (1): 100–1 (in Russ.)].
  5. Gosudarstvennyj reestr lekarstvennyh sredstv [State Register of Medicines. (in Russ.)]. Rezhim dostupa / Access mode: https://grls.rosminzdrav.ru/Default.aspx
  6. Gromova O.A., Torshin I.Ju., Egorova E.Ju. Omega-3 polinenasyschennye zhirnye kisloty i kognitivnoe razvitie detej. Voprosy sovremennoj pediatrii. 2011; 10 (1): 66–72 [Gromova O.A., Torshin I.Yu., Yegorova Y.Yu. Omega-3 polyunsaturated fatty acids and cognitive development of children. Current Pediatrics. 2011; 10 (1): 66–72 (in Russ.)].
  7. Egorova A.V., Mykol'nikova E.S. Preparat Irifrin 2,5% v terapii komp'juternogo zritel'nogo sindroma. RMZh. Klinicheskaja oftal'mologija. 2009; 1: 30–3 [Egorova A.V., Mykolnikova E.S. Irifrin 2.5% in treatment of computer syndrome. RMJ. Clinical Ophthalmology. 2009; 1: 30–3 (in Russ.)].
  8. Zaharova M.A., Kuroedov A.V. Primenenie antioksidantov v kompleksnoj terapii komp'juternogo zritel'nogo sindroma. RMZh. Klinicheskaja oftal'mologija. 2016; 1: 54–9 [Zakharova M.A., Kuroyedov A.V. Antioxidants in complex treatment of computer vision syndrome. RMJ. Clinical ophthalmology. 2016; 1: 54–9 (in Russ.)].
  9. Zaharova M.A., Oganezova Zh.G. Sovremennye podhody k terapii komp'juternogo zritel'nogo sindroma. RMZh. Klinicheskaja oftal'mologija. 2018; 1: 50–3 [Zakharova M.A., Oganezova J.G. Modern approaches to the therapy of computer visual syndrome. RMJ. Clinical ophthalmology. 2018; 1: 50–3 (in Russ.)].
  10. Ibragimova D.I. Vybor algoritma terapii razlichnyh klinicheskih form porazhenija rogovitsy pri sindrome suhogo glaza (eksperimental'no-klinicheskoe issledovanie). Avtoref. dis. ... kand. med. nauk. M.: Mosk. nauch.-issled. in-t glaz. boleznej im. Gel'mgol'tsa, 2014 [Ibragimova D.I. Choice of an algorithm for the treatment of various clinical forms of corneal lesions in dry eye syndrome (experimental and clinical study). Avtoref. dis. ... kand. med. nauk. M.: Mosk. nauch.-issled. in-t glaz. boleznei im. Gel’mgol’tsa, 2014 (in Russ.)].
  11. Isakova E.V. Rabota s komp'juterom i komp'juternyj zritel'nyj sindrom. Vjatskij med vestn. 2011; 3: 32–5 [Isakova E.V. Work connected to computer and computer vision syndrome. Vyatskii med vestn. 2011; 3: 32–5 (in Russ.)].
  12. Kalmykov R.V., Kamenskih T.G. Preparaty na osnove gidroksipropil guara v lechenii sindroma suhogo glaza u patsientov, zanjatyh v tsementnom proizvodstve. Meditsinskij vestnik Bashkortostana. 2016; 11 (1): 16–8 [Kalmykov R.V., Kamenskikh T.G. Preparations based on hydroxypropyl-guar in the treatment of the «dry eye» syndrome in patients involved in cement manufacture. Medical Bulletin of Bashkortostan. 2016; 11 (1): 16–8 (in Russ.)].
  13. Kats D.V. Vozmozhnosti primenenija kompleksnyh preparatov, vkljuchajuschih antotsianozidy, v lechenii i profilaktike oftal'mologicheskih zabolevanij. RMZh. Klinicheskaja oftal'mologija. 2014; 3: 180–3 [Katz D.V. Possibilities of usage of complex drugs including anthocyanozides in the treatment and prophylaxis of ophthalmologic diseases. RMJ. Clinical Ophthalmology. 2014; 3: 180–3 (in Russ.)].
  14. Kiseleva T.N. Rol' antotsianozidov v korrektsii narushenij mikrotsirkuljatsii i gemodinamiki glaza pri oftal'mopatologii. Rossijskij oftal'mologicheskij zhurnal. 2013; 1: 108–12 [Kiseleva T.N. The role of anthocyanosides in the correction of eye microcirculation and hemodynamic disorders in ophthalmic pathology. Russian Ophthalmological Journal. 2013; 1: 108–12 (in Russ.)].
  15. Kiseleva T.N., Lagutina Ju.M., Kravchuk E.A. Sovremennye aspekty patogeneza, kliniki i medikamentoznogo lechenija neekssudativnyh form vozrastnoj makuljarnoj degeneratsii. RMZh. Klinicheskaja oftal'mologija. 2006; 3: 99–103 [Kiseleva T.N., Lagutina Yu.M., Kravchuk E.A. Modern aspects of pathogenesis, clinic and treatment of non-exudative forms of age–related macular degeneration. RMJ. Clinical Ophthalmology. 2006; 3: 99–103 (in Russ.)].
  16. Kiseleva T.N., Polunin G.S., Budzinskaja M.V. i dr. Sovremennye podhody k lecheniju i profilaktike vozrastnoj makuljarnoj degeneratsii. RMZh. Klinicheskaja oftal'mologija. 2007; 2: 78–82 [Kiseleva T.N., Polunin G.S., Budzinskaya M.V. et al. Modern approaches to treatment and prophylaxis of age related macular degeneration. RMJ. Clinical Ophthalmology. 2007; 2: 78–82 (in Russ.)].
  17. Komp'juternyj zritel'nyj sindrom v praktike vracha-oftal'mologa [Computer vision syndrome in the practice of an ophthalmologist. (in Russ.)]. Rezhim dostupa / Access mode: https://medvestnik.ru/content/medarticles/Komputernyi-zritelnyi-sindrom-v-praktike-vracha-oftalmologa.html
  18. Krylov S.V., Kim O.A. Rezul'taty sravnitel'noj otsenki effektivnosti terapevticheskogo dejstvija i perenosimosti preparatov Sistejn® i Sistejn ul'tra®. Oftal'mologija. 2011; 8 (3): 44–7 [Krylov S.V., Kim O.A. Results of a comparative estimation of efficiency and tolerance of preparations Systane® and Systane®. Ophthalmology. 2011; 8 (3): 44–7 (in Russ.)].
  19. Loskutov I.A., Korneeva A.V. Diagnostika i terapija sindroma suhogo glaza v poliklinicheskih uslovijah. Effektivnaja farmakoterapija. 2019; 15 (33): 24–9 [Loskutov I. A., Korneeva A.V. Diagnosis and Therapy of Dry Eye Syndrome in Ambulatory Care. Effective pharmacotherapy. 2019; 15 (33): 24–9 (in Russ.)]. DOI:10.33978/2307-3586-2019-15-33-24-28
  20. Majchuk Ju.F., Jani E.V. Issledovanie effektivnosti primenenija preparata oftolik v lechenii bolezni suhogo glaza. RMZh. Klinicheskaja oftal'mologija. 2009; 10 (1): 33–6 [Maichuk Yu.F., Yani E.V. Study of effect of Ophtolique in the treatment of dry eye syndrome. RMJ. Clinical ophthalmology. 2009; 10 (1): 33–6 (in Russ.)].
  21. Malishevskaja T.N., Dolgova I.G., Ortenberg E.A. Izuchenie vlijanija preparatov Striks i Striks forte na zritel'nye funktsii bol'nyh s vozrastnoj patologiej setchatki i zritel'nogo nerva. RMZh. Klinicheskaja oftal'mologija. 2008; 1: 20–4 [Malishevskaya T.N., Dolgova D.L., Ortenberg E.A. The investigation of Strix and Strix forte effect on visual functions of patients with retinal and optic nerve pathology. RMJ. Clinical Ophthalmology. 2008; 1: 20–4 (in Russ.)].
  22. Mal'hanov V.B., Gumerova E.I., Matjuhina E.N. Terapevticheskaja effektivnost' preparata «Sistejn Ul'tra» pri sindrome suhogo glaza [Malkhanov V.B., Gumerova E.I., Matyukhina E. N. Therapeutic efficacy of the drug «Sistein Ultra» in dry eye syndrome (in Russ.)]. Rezhim dostupa / Access mode: https://eyepress.ru/article.aspx?11411
  23. Mihel' V.D., Bozhovich Ju.V., Diogenova M.A. i dr. Effektivnost' preparata OKUflesh® pri zabolevanijah perednego otdela glaza u detej i vzroslyh. Lіkarju-praktiku. 2013; 1 (93) [Mikhel V.D., Bozhovich Yu.V., Diogenova M.A. et al. The effectiveness of the drug Okuflesh® in diseases of the anterior part of the eye in children and adults. Likaru-practice. 2013; 1 (93) (in Ukraine)]. Rezhim dostupa / Access mode. https://www.umj.com.ua/article/53341/effektivnost-preparata-okuflesh-sup-sup-pri-zabolevaniyax-perednego-otdela-glaza-u-detej-i-vzroslyx
  24. Nagorskij P.G. Primenenie antioksidantov v kompleksnoj terapii komp'juternogo zritel'nogo sindroma. RMZh. Klinicheskaja oftal'mologija. 2006; 1: 38–40 [Nagorskii P.G. Usage of antioxidants in the complex treatment of computer visual syndrome. RMJ. Clinical Ophthalmology. 2006; 1: 38–40 (in Russ.)].
  25. Neroev V.V., Sarygina O.I. Otsenka klinicheskoj effektivnosti antioksidantnogo kompleksa Striks® forte v terapii vozrastnoj makuljarnoj degeneratsii. RMZh. Klinicheskaja oftal'mologija. 2007; 3: 101–3 [Neroev V.V., Sarygina O.I. Evaluation of clinical efficacy of antioxidant complex Strix Forte in the treatment of age–related macular degeneration. RMJ. Clinical Ophthalmology. 2007; 8: 101–3 (in Russ.)].
  26. Ovechkin I.G., Agafonov N.N., Ovechkin N.I. i dr. Primenenie funktsional'noj korrektsii organa zrenija patsientam – operatoram zritel'nogo profilja s pozitsij sovremennyh trebovanij k meditsinskoj reabilitatsii. Rossijskij oftal'mologicheskij zhurnal. 2015; 1: 90–7 [Ovechkin I.G., Agafonov N.N., Ovechkin N.I. et al. Functional correction of the eye in operators engaged in extensive visual work from the viewpoint of modern requirements to medical rehabilitation. Russian Ophthalmological Journal. 2015; 1: 90–7 (in Russ.)].
  27. Prozherina Ju., Il'juhina E. Innovatsionnye podhody k resheniju problemy sindroma «suhogo glaza». Remedium. 2018; 1–2: 55–8 [Prozherina Yu., Ilyukhina E. Innovative approaches to address the dry eye syndrome issue. Remedium. 2018; 1–2: 55–8 (in Russ.)]. DOI: 10.21518/1561-5936-2018-1-2-55-58
  28. Romanenko I.A. Effektivnost' preparatov cherniki v oftal'mologii: klinicheskie nabljudenija. RMZh. Klinicheskaja oftal'mologija. 2011; 1: 32–4 [Romanenko I.A. Efficiency of bilberry drugs in ophthalmology: clinical observations (Literary review). RMJ. Clinical Ophthalmology. 2011; 1: 32–4 (in Russ.)].
  29. Safonova T.N., Surnina Z.V., Zajtseva G.V. Sravnitel'naja harakteristika osmoljarnosti, slezoproduktsii i sostojanija epitelija rogovitsy posle instilljatsij preparatov vizomitin i gipromellozy. Meditsinskij sovet. 2020; 21: 249–55 [Safonova T.N., Surnina Z.V., Zaitseva G.V. Comparative characteristics of osmolarity, tear production and state of the corneal epithelium after instillations of the preparations Visomitin and hypromellose. Meditsinskiy sovet = Medical Council. 2020; 21: 249–55 (in Russ.)]. DOI: 10.21518/2079-701X-2020-21-249-255
  30. Sardalova L.R., Sysoeva A.I. Analiz assortimenta glaznyh kapel' i gelej, primenjaemyh pri sindrome «suhih glaz». V kn.: Molodezh', nauka, meditsina. Tezisy 66-j Vserossijskoj mezhvuzovskoj studencheskoj nauchnoj konferentsii s mezhdunarodnym uchastiem. Tver', 2021; s. 246–7 [Sardalova L.R., Sysoeva A.I. Analysis of the range of eye drops and gels used in the «dry eye» syndrome. In the book: Youth, science, medicine. Abstracts of the 66th All-Russian Interuniversity Student Scientific Conference with International participation. Tver, 2021; r. 246–7 (in Russ.)].
  31. Sidorenko E.I., Markova E.Ju., Matveev A.V. Komp'juternyj zritel'nyj sindrom. Rossijskaja pediatricheskaja oftal'mologija. 2009; 2: 31–3 [Sidorenko E.I., Markova E. Yu., Matveyev A.V. Computer vision syndrome. Russian Pediatric Ophthalmology. 2009; 2: 31–3 (in Russ.)].
  32. Spravochnik lekarstv i tovarov aptechnogo assortimenta. RLS [Directory of medicines and pharmacy products. RLS (in Russ.)]. URL: https://www.rlsnet.ru/
  33. Jani E.V., Katargina L.A., Chesnokova N.B. i dr. Pervyj opyt ispol'zovanija preparata «Vizomitin» v terapii «Suhogo glaza». Prakticheskaja meditsina. 2012; 59 (4): 134–7 [Yani E.V., Katargina L.A., Chesnokova N.B. et al. The first experience of using the drug vizomitin in the treatment of «dry eyes». Practical medicine. 2012; 59 (4): 134–7 (in Russ.)].
  34. Amrane M., Creuzot-Garcher C., Robert P.-Y. et al. Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease – a randomised comparative study. J Fr Ophtalmol. 2014; 37 (8): 589–98. DOI: 10.1016/j.jfo.2014.05.001
  35. Aragona P., Papa V., Micali A. et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002; 86: 181–4. DOI: 10.1136/bjo.86.2.181
  36. Barar A., Apatachioaie I.D., Apatachioaie C. et al. Ophthalmologist and «computer vision syndrome». Oftalmologia. 2007; 51 (3): 104–9.
  37. Chong E.W., Kreis A.J., Wong T.Y. et al. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. Arch Ophthalmol. 2008; 126 (6): 826–33. DOI: 10.1001/archopht.126.6.826
  38. Fogagnolo P., Quisisana C., Caretti A. et al. Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial. Clin Ophthalmol. 2020; 14: 1651–63. DOI: 10.2147/OPTH.S258081
  39. Haji-Ali-Nili N., Khoshzaban F., Karimi M. Lifestyle Determinants on Prevention and Improvement of Dry Eye Disease from the Perspective of Iranian Traditional Medicine. Iran J Med Sci. 2016; 41 (3 Suppl): S39.
  40. Heemskerk J.W., Vossen R.C., van Dam-Mieras M.C. Polyunsaturated fatty acids and function of platelets and endothelial cells. Curr Opin Lipidol. 1996; 7 (1): 24–9. DOI: 10.1097/00041433-199602000-00006
  41. Jaiswal S., Asper L., Long J. et al. Ocular and visual discomfort associated with smartphones, tablets and computers: what we do and do not know. Clin Exp Optom. 2019; 102 (5): 463–77. DOI: 10.1111/cxo.12851
  42. Mersha G.A., Hussen M.S., Belete G.T. et al. Knowledge about Computer Vision Syndrome among Bank Workers in Gondar City. Northwest Ethiopia. 2020; 14: 2561703. DOI: 10.1155/2020/2561703
  43. Mrukwa-Kominek E., Baranska K., Jadczyk K. First clinical reports on the application of the modern dual-polymer formula in aqueous deficiency dry eye syndrome: Polish observations. 20th ESCRS Winter Meeting 26–28 February 2016, ATHENS, Greece.
  44. Munshi S., Varghese A., Dhar-Munshi S. Computer vision syndrome-A common cause of unexplained visual symptoms in the modern era. Int J Clin Pract. 2017; 71 (7). DOI: 10.1111/ijcp.12962
  45. Randolph S.A. Computer Vision Syndrome. Workplace Health Saf. 2017; 65 (7): 328. DOI: 10.1177/2165079917712727
  46. SanGiovanni J.P., Agrón A., Meleth A.D. et al. ω-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. Am J Clin Nutr. 2009; 90 (6): 1601–16. DOI: 10.3945/ajcn.2009.27594
  47. Simmons P.A., Carlisle-Wilcox C., Chen R. et al. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial. Clin Ther. 2015; 37 (4): 858–68. DOI: 10.1016/j.clinthera.2015.01.001